雄激素受体与循环雄激素结合，进而调控各种信号通路及靶基因的转录，参与多种生物学过程。雄激素受体在多种肿瘤中异常表达，尤其是在激素依赖性肿瘤中起重要作用，针对雄激素受体的靶向治疗是目前激素依赖性肿瘤的热门研究方向。本文主要对近年来雄激素受体在激素依赖性恶性肿瘤前列腺癌、乳腺癌、肝癌和子宫内膜癌等中作用的研究进展进行综述，对目前雄激素受体在激素依赖性恶性肿瘤中的作用进行知识及不同观点梳理，从而为相关领域的研究者提供理论参考。

[1] LI D,ZHOU W,PANG J,et al.A magic drug target:androgen receptor[J].Med Res Rev,2019,39(5):1485-1514.
[2] BENNETT N C,GARDINER R A,HOOPER J D,et al.Molecular cell biology of androgen receptor signalling[J].Int J Biochem Cell Biol,2010,42(6):813-827.
[3] RANA K,DAVEY R A,ZAJAC J D.Human androgen deficiency:insights gained from androgen receptor knockout mouse models[J].Asian J Androl,2014,16(2):169-177.
[4] MATSUMOTO T,SHIINA H,KAWANO H,et al.Androgen receptor functions in male and female physiology[J].J Steroid Biochem Mol Biol,2008,109(3-5):236-241.
[5] AURILIO G,CIMADAMORE A,MAZZUCCHELLI R,et al.Androgen receptor signaling pathway in prostate cancer:from genetics to clinical applications[J].Cells,2020,9(12):2653.
[6] HICKEY T E,SELTH L A,CHIA K M,et al.The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer[J].Nat Med,2021,27(2):310-320.
[7] YU X,YI P,HAMILTON R A,et al.Structural insights of transcriptionally active,full-length androgen receptor coactivator complexes[J].Mol Cell,2020,79(5):812-823.e4.
[8] MATSUMOTO T,SAKARI M,OKADA M,et al.The androgen receptor in health and disease[J].Annu Rev Physiol,2013,75:201-224.
[9] LEUNG J K,SADAR M D.Non-genomic actions of the androgen receptor in prostate cancer[J].Front Endocrinol(Lausanne),2017,8:2.
[10] SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[11] EVANS A J.Treatment effects in prostate cancer[J].Mod Pathol,2018,31(S1):S110-S121.
[12] Cancer Genome Atlas Research Network.The molecular taxonomy of primary prostate cancer[J].Cell,2015,163(4):1011-1025.
[13] TAPLIN M E,BUBLEY G J,SHUSTER T D,et al.Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer[J].N Engl J Med,1995,332(21):1393-1398.
[14] VISAKORPI T,HYYTINEN E,KOIVISTO P,et al.In vivo amplification of the androgen receptor gene and progression of human prostate cancer[J].Nat Genet,1995,9(4):401-406.
[15] SUR I,TAIPALE J.The role of enhancers in cancer[J].Nat Rev Cancer,2016,16(8):483-493.
[16] PUNGSRINONT T,KALLENBACH J,BANIAHMAD A.Role of PI3K-AKT-mTOR pathway as a pro-survival signaling and resistance-mediating mechanism to therapy of prostate cancer[J].Int J Mol Sci,2021,22(20):11088.
[17] MURILLO-GARZON V,KYPTA R.WNT signalling in prostate cancer[J].Nat Rev Urol,2017,14(11):683-696.
[18] CARVER B S,CHAPINSKI C,WONGVIPAT J,et al.Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer[J].Cancer Cell,2011,19(5):575-586.
[19] SCHER H I,FIZAZI K,SAAD F,et al.Increased survival with enzalutamide in prostate cancer after chemotherapy[J].N Engl J Med,2012,367(13):1187-1197.
[20] HU R,DAWOOD S,HOLMES M D,et al.Androgen receptor expression and breast cancer survival in postmenopausal women[J].Clin Cancer Res,2011,17(7):1867-1874.
[21] ELEBRO K,BORGQUIST S,SIMONSSON M,et al.Combined androgen and estrogen receptor status in breast cancer:treatment prediction and prognosis in a population-based prospective cohort[J].Clin Cancer Res,2015,21(16):3640-3650.
[22] ASTVATSATURYAN K,YUE Y,WALTS A E,et al.Androgen receptor positive triple negative breast cancer:clinicopathologic,prognostic,and predictive features[J].PLoS One,2018,13(6):e0197827.
[23] MCGLYNN K A,PETRICK J L,EL-SERAG H B.Epidemiology of hepatocellular carcinoma[J].Hepatology,2021,73(Suppl 1):4-13.
[24] FENG H,CHENG A S,TSANG D P,et al.Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives beta-catenin/T cell factor-dependent hepatocarcinogenesis[J].J Clin Invest,2011,121(8):3159-3175.
[25] NAGARAJU G P,DARIYA B,KASA P,et al.Epigenetics in hepatocellular carcinoma[J].Semin Cancer Biol,2022,86(Pt 3):622-632.
[26] SONG H,YU Z,SUN X,et al.Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/beta-catenin signaling[J].EBioMedicine,2018,35:155-166.
[27] ZHOU H C,LIU C X,PAN W D,et al.Dual and opposing roles of the androgen receptor in VETC-dependent and invasion-dependent metastasis of hepatocellular carcinoma[J].J Hepatol,2021,75(4):900-911.
[28] CROSBIE E J,KITSON S J,MCALPINE J N,et al.Endometrial cancer[J].Lancet,2022,399(10333):1412-1428.
[29] WU X,ZHONG X,HUO X,et al.The clinicopathological significance and prognostic value of androgen receptor in endometrial carcinoma:a Meta-analysis[J].Front Oncol,2022,12:905809.
[30] MAHDI Z,ABDULFATAH E,PARDESHI V,et al.The impact of androgen receptor expression on endometrial carcinoma recurrence and survival[J].Int J Gynecol Pathol,2017,36(5):405-411.
[31] WU S,YU K,LIAN Z,et al.Molecular regulation of androgen receptors in major female reproductive system cancers[J].Int J Mol Sci,2022,23(14):7556.
[32] SAHLIN L,NORSTEDT G,ERIKSSON H.Androgen regulation of the insulin-like growth factor-Ⅰ and the estrogen receptor in rat uterus and liver[J].J Steroid Biochem Mol Biol,1994,51(1-2):57-66.
[33] QIU M,BAO W,WANG J,et al.FOXA1 promotes tumor cell proliferation through AR involving the Notch pathway in endometrial cancer[J].BMC Cancer,2014,14:78.
[34] KOIVISTO C S,PARRISH M,BONALA S B,et al.Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-Ⅰ endometrial carcinoma[J].Neoplasia,2020,22(10):484-496.
[35] WESTIN S,FELLMAN B,YUAN Y,et al.ENPAC:phase Ⅱ trial with safety lead of enzalutamide in combination with paclitaxel and carboplatin for advanced or recurrent endometrioid endometrial adenocarcinoma[J].Gynecol Oncol,2021,162:S42-S43.
[36] PARK B Y,GRISHAM R N,DEN HOLLANDER B,et al.Tumor inhibition by enzalutamide in a xenograft model of ovarian cancer[J].Cancer Invest,2016,34(10):517-520.